Hyperinsulinism: Clinical Trials

336 trials for Hyperinsulinism, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

336 completed. 336 Phase 2, 54 Phase 3, 48 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2336Completed 336
Phase 354Completed 54
Phase 148Completed 48

Follow Hyperinsulinism: new trials by email Literature Review of Hyperinsulinism trials Research Report on Hyperinsulinism

Trials (filtered) newest first · largest first

All 336 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Topical Insulin on Healing Rate of Pemphigus Lesions
insulin glargine, human insulin, 0.9% Normal Saline - Pemphigus Vulgaris, Skin Erosion
Phase 2CompletedAlexandria University202024-06-222026-03-10
Polyamine Treatment in Elderly Patients With Coronary Artery Disease
Spermidine, Placebo - Ischemic Heart Disease, Myocardial Infarction
Phase 2CompletedUniversity of Aarhus1872024-01-012026-07-01
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
INV-202, Placebo - Obesity, Metabolic Syndrome
Phase 2CompletedInversago Pharma Inc.2432023-09-082025-06-05
Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Vericiguat, Placebo - Metabolic Syndrome, Coronary Microvascular Dysfunction
Phase 2CompletedJohns Hopkins University452023-06-162026-01-27
Hyperinsulinemia in Prediabetes Mediated by Interleukin-1β
Anakinra, Placebo - Hyperinsulinemia, PreDiabetes
Phase 2CompletedUniversity Hospital, Basel, Switzerland202023-06-152025-01-29
Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)
Ursolic Acid, Strength Training - Spinal Cord Injuries, Tetraplegia
Phase 2CompletedUniversity of Miami102023-03-272025-05-21
Everolimus Aging Study
Everolimus 0.5 MG once per day, Everolimus 5 MG once per week, Placebo once per day - Aging, Insulin Resistance
Phase 2CompletedUniversity of Wisconsin, Madison1062023-03-242026-09-04
The Effects of Glucagon on Hepatic Metabolism
Glucagon response study - Obesity, Type2diabetes
Phase 1 / Phase 2CompletedAdrian Vella212022-10-202026-11-04
Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care
Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy - Type 1 Diabetes, Diabetes Mellitus, Type 1
Phase 2 / Phase 3CompletedMcGill University Health Centre/Research Institute of the McGill University Health Centre282022-10-022025-01-22
A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome.
Metformin Extended Release Oral Tablet - Metabolic Syndrome, HIV Seropositivity
Phase 2CompletedUniversity of Stellenbosch302022-08-112025-10-06
Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease
dulaglutide injection - Chronic Kidney Diseases
Phase 2CompletedVanderbilt University Medical Center72022-03-152025-04-20
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
Semaglutide, 1.34 mg/mL, Placebo - Schizophrenia, Prediabetic State
Phase 2CompletedJan Frystyk1542022-01-012024-07-08
Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents With Obesity
Colchicine, Placebo - Obesity, Insulin Resistance
Phase 2CompletedEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)1522021-11-082025-09-05
Treatment of Post-bariatric Hypoglycaemia
Dasiglucagon, HyoPen, Placebo - Hyperinsulinemic Hypoglycemia, Postprandial Hypoglycemia
Phase 2CompletedFilip Krag Knop242021-08-202023-02-02
A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
Orticumab, Placebo - Psoriasis, Inflammation
Phase 2CompletedAbcentra772021-06-302026-05-11
eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications - Depression, Major Depressive Disorder
Phase 2CompletedIndiana University462020-10-142023-11-02
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
dasiglucagon, Placebo - Congenital Hyperinsulinism
Phase 2 / Phase 3CompletedZealand Pharma122020-06-192025-03-14
An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism
RZ358 Sequential Group Cohort 1, RZ358 Sequential Group Cohort 2, RZ358 Sequential Group Cohort 3 - Congenital Hyperinsulinism
Phase 2CompletedRezolute232020-02-242025-05-28
Intranasal Insulin in Parkinson's Disease
Regular Novolin R, Placebo - Parkinson Disease
Phase 2CompletedHealthPartners Institute312020-02-042026-02-11
Causal Mechanisms in Adolescent Arterial Stiffness
CS+, CS- - Lipid Disorder, Dyslipidemias
Phase 2CompletedBaylor College of Medicine722020-02-012026-11-02

Showing 20 of 336. Sign in to see all of them.

Narrower conditions

Insulin Resistance (233)  ·  Metabolic Syndrome (124)  ·  Obesity (64)  ·  Diabetes Mellitus, Type 2 (56)  ·  Diabetes Mellitus (52)  ·  Diabetes Mellitus, Type 1 (34)  ·  Hypoglycemia (25)  ·  Inflammation (20)  ·  Glucose Intolerance (19)  ·  Hypertension (18)  ·  Non-alcoholic Fatty Liver Disease (17)  ·  Overweight (17)  ·  Cardiovascular Diseases (13)  ·  Fatty Liver (13)

Broader conditions

Nutritional and Metabolic Diseases (335)  ·  Glucose Metabolism Disorders (330)  ·  Metabolic Diseases (329)  ·  Endocrine System Diseases (133)  ·  Pathological Conditions, Signs and Symptoms (118)  ·  Signs and Symptoms (92)  ·  Insulin Resistance (85)  ·  Nutrition Disorders (85)  ·  Body Weight (84)  ·  Overnutrition (82)  ·  Diabetes Mellitus (78)  ·  Overweight (65)  ·  Pathologic Processes (41)  ·  Immune System Diseases (40)

Interventions

Metformin (30)  ·  Insulin (23)  ·  Pioglitazone (14)  ·  Exercise (12)  ·  Cholecalciferol (10)  ·  Glucagon (8)  ·  Rosiglitazone (8)  ·  salicylsalicylic acid (8)  ·  Atorvastatin (6)  ·  Insulin Aspart (6)  ·  Insulin Lispro (6)  ·  Methods (5)  ·  Resveratrol (5)  ·  Saline Solution (5)  ·  Vitamin D (5)

Sponsors

Institut de Recherches Cliniques de Montreal (13)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (11)  ·  University of Guadalajara (10)  ·  Massachusetts General Hospital (6)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (5)  ·  Joslin Diabetes Center (5)  ·  University of Aarhus (5)  ·  Children's Hospital of Philadelphia (4)  ·  Emory University (4)  ·  Tehran University of Medical Sciences (4)  ·  University of Pennsylvania (4)  ·  University of Toronto (4)  ·  Vanderbilt University Medical Center (4)  ·  Albert Einstein College of Medicine (3)  ·  Assistance Publique - Hôpitaux de Paris (3)

Countries

United States (158)  ·  Canada (44)  ·  Denmark (16)  ·  Germany (16)  ·  Mexico (14)  ·  Italy (10)  ·  France (9)  ·  Netherlands (9)  ·  United Kingdom (8)  ·  Iran (6)  ·  Sweden (6)  ·  Switzerland (6)  ·  Finland (5)  ·  Spain (5)  ·  Australia (4)

Top investigators

Jack A Yanovski, M.D. (5)  ·  Allison B. Goldfine, MD (4)  ·  Raika Jamali, M.D. (4)  ·  Valerio Nobili, MD (3)  ·  Xu Lin, MD, PhD (3)  ·  Alp Ikizler, MD (2)  ·  Andre Marette, PhD (2)  ·  Bahram H. Arjmandi, PhD, RD (2)  ·  Bruno Geloneze, MD, PhD (2)  ·  Christoph Kapitza, MD (2)  ·  Cyndya Shibao, MD (2)

Results publications

PMID 19889232, PMID 20826632, PMID 21070531, PMID 25091629, PMID 10480510, PMID 10523015, PMID 10868854, PMID 10963727, PMID 11411567, PMID 11443202, PMID 11556815, PMID 12145010, PMID 12523673, PMID 12622244, PMID 15070752, PMID 15168555, PMID 15220351, PMID 15333514, PMID 15713712, PMID 15949871, PMID 16054141, PMID 16157765, PMID 16452557, PMID 16614616, PMID 16626303, PMID 16636217, PMID 16818482, PMID 1695875, PMID 17069794, PMID 17086191, PMID 17112576, PMID 17135615, PMID 17206944, PMID 17236890, PMID 17245174, PMID 17283239, PMID 17429083, PMID 17517446, PMID 17563345, PMID 17578889, PMID 17682120, PMID 17684509, PMID 17895314, PMID 17959861, PMID 17986612, PMID 18266981, PMID 18274222, PMID 18460557, PMID 18726828, PMID 18769731

NIH funding

2009 (2), 2017 (2), U01DK074556 (2), UL1RR024150 (2), 1UH3TR001372-01 (1), 2005 (1), 2019 (1), 2023 (1), F32DK068902 (1), I01CX000982 (1), K23AG019161 (1), K23HL103976 (1), K23RR023335 (1), KL2RR024151 (1), P30DK019525 (1)